# Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With Hematologic Malignancies

> **NCT04748185** · — · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 358 (actual)

## Conditions studied

- Monoclonal B-Cell Lymphocytosis
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- B-cell Non Hodgkin Lymphoma
- Hodgkin Lymphoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04748185
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-28
- **Primary completion:** 2022-07-13
- **Final completion:** 2022-07-13
- **Target enrollment:** 358 (ACTUAL)
- **Last updated:** 2023-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04748185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04748185, "Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With Hematologic Malignancies". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04748185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*